Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, ...
Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold play in the AI sector. In a span of a week, Tempus AI, Inc. (NASDAQ:TEM) made ...
An international team led by researchers at the University of California (UC) San Diego School of Medicine reports that it has validated a more inclusive and comprehensive genetic tool for predicting ...
Radiographic-pathologic concordance in the workup of locally radiorecurrent prostate cancer. Detection of true positive M1 lesions by 18F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results